Simultaneous determination of rifampicin and efavirenz in plasma

Therapeutic Drug Monitoring

Volumn 24, Issue 5, 2002, Pages 670-674

  Boffito, Marta ^a   Tija, John ^a   Reynolds, Helen E ^a   Hoggard, Patrick G ^a   Bonora, Stefano ^a   Di Perri, Giovanni ^a   BacK, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiretrovirals; Efavirenz; High performance liquid chromatography; Rifampicin; Tuberculosis

Indexed keywords

CYTOCHROME P450; EFAVIRENZ; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; PHARMACOKINETICS; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZINES; RIFAMPIN; TUBERCULOSIS;

EID: 0036785995     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200210000-00015     Document Type: Article

References (17)

1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
2. Luber AD, Hardy WD. Therapeutic drug monitoring: step by step. Medscape HIV/AIDS 2001. Available at: http://www.medscape. com.
3. Back DJ, Khoo SH, Gibbons SE, et al. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001;51:301-8.
4. Nierengarten MB. Tuberculosis in the 21st century: still not history. Medscape Infectious Disease 2001. Available at: http://www.medscape.com.
5. Radner DB. Toxicologic and pharmacologic aspects of rifampin. Chest 1973;64:213-6.
6. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS society-USA Panel. JAMA 2000;283:381-90.
7. Marzolini C, Talenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-5.
8. Lopez-Cortes LF, Ruiz R, Viciana P et al. Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection [Abstract 32]. In: Program and Abstracts from the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
9. Resnik L, Veren K, Salahuddin SZ, et al. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA 1986;255:1887-91.
10. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
11. Veldkamp AI, van Heeswijk RP, Meenhorst PL, et al. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999;734: 55-61.
12. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999;48: 712-5.
13. Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and concentrations attained in human blood. Am Rev Resp Dis 1968;98:923-32.
14. Hung CC, Chen MY, Hsieh SM, et al. Efficacy of highly active antiretroviral therapy combined with rifamycin-containing antituberculous therapy in HIV-1 infected patients with tuberculosis [Abstract 548]. In: Program and Abstracts from the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
15. Panchagnula R, Sood A, Sharda N, et al. Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. J Pharm Biomed Anal 1999;18:1013-20.
16. Jamaluddin AB, Sarwar G, Rahim MA, et al. High performance liquid chromatographic assay of rifampicin in human serum. J Chromatogr B Biomed Sci Appl 1990;525:495-7.
17. Villani P, Pregnolato M, Banfo S, et al. High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasma. Ther Drug Monit 1999;21:346-50.